Xintian Pharma announced that it expects the net profit attributable to shareholders of the listed company for the period from January 1, 2025, to June 30, 2025, to be between 5 million and 7 million yuan, a decrease of 83.52% to 76.93% compared to the same period last year, which was 30.3395 million yuan. The net profit after deducting non-recurring gains and losses is expected to be between 3 million and 4.2 million yuan, a decrease of 89.83% to 85.77% compared to the same period last year, which was 29.513 million yuan. The basic earnings per share are expected to be between 0.0205 yuan/share and 0.0287 yuan/share, a decrease compared to the same period last year's 0.1312 yuan/share